4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $38.56.

Several equities research analysts have recently issued reports on the company. Leerink Partners lowered their price objective on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research note on Monday, January 13th. Royal Bank of Canada dropped their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Chardan Capital reissued a “buy” rating and issued a $39.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Morgan Stanley dropped their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research report on Monday, January 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Saturday, January 18th.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently modified their holdings of FDMT. Algert Global LLC boosted its position in 4D Molecular Therapeutics by 20.6% during the second quarter. Algert Global LLC now owns 16,588 shares of the company’s stock valued at $348,000 after purchasing an additional 2,828 shares in the last quarter. nVerses Capital LLC purchased a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth approximately $40,000. The Manufacturers Life Insurance Company raised its stake in shares of 4D Molecular Therapeutics by 25.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,975 shares of the company’s stock worth $398,000 after acquiring an additional 3,850 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in 4D Molecular Therapeutics by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock valued at $108,000 after acquiring an additional 3,922 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in 4D Molecular Therapeutics in the third quarter valued at approximately $57,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Trading Down 4.3 %

Shares of NASDAQ:FDMT opened at $4.66 on Friday. The company has a market cap of $215.43 million, a price-to-earnings ratio of -1.64 and a beta of 2.81. 4D Molecular Therapeutics has a 12 month low of $4.43 and a 12 month high of $36.25. The company has a 50-day moving average price of $6.31 and a 200 day moving average price of $10.91.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.